Cover Image
市場調查報告書

Rexahn Pharmaceuticals, Inc.- 產品平台檢討

Rexahn Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 203740
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Rexahn Pharmaceuticals, Inc.- 產品平台檢討 Rexahn Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月22日 內容資訊: 英文 40 Pages
簡介

Rexahn Pharmaceuticals, Inc.是總公司設置於美國的生物製藥企業,正在開發、製造癌症治療藥。其開發平台上有阻礙腫瘤成長和黑色素瘤轉移的低分子治療藥、阻礙DNA及RNA合成、誘導細胞凋亡的核苷、阻礙癌細胞的信號蛋白質的磷酸化Akt1活性化的抗癌劑候補藥等。

本報告提供Rexahn Pharmaceuticals, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Rexahn Pharmaceuticals, Inc. 的基本資料

  • Rexahn Pharmaceuticals, Inc. 概要
  • 主要資訊
  • 企業資料

Rexahn Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Rexahn Pharmaceuticals, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Rexahn Pharmaceuticals, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Rexahn Pharmaceuticals, Inc.:藥物簡介

  • RX-0201
  • RX-3117
  • RX-5902
  • RX-0047N
  • RX-0201N
  • RX-1792
  • RX-21101
  • RX-8243
  • Small Molecules for Cancer

Rexahn Pharmaceuticals, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Rexahn Pharmaceuticals, Inc. :最新的開發平台資訊

Rexahn Pharmaceuticals, Inc. :開發暫停中的計劃

Rexahn Pharmaceuticals, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06965CDB

Summary

Global Markets Direct's, 'Rexahn Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Rexahn Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Rexahn Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Rexahn Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Rexahn Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Rexahn Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Rexahn Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Rexahn Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Rexahn Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Rexahn Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rexahn Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Rexahn Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Rexahn Pharmaceuticals, Inc. Snapshot
    • Rexahn Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Rexahn Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Rexahn Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Rexahn Pharmaceuticals, Inc. - Pipeline Products Glance
    • Rexahn Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Rexahn Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Rexahn Pharmaceuticals, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Rexahn Pharmaceuticals, Inc. - Drug Profiles
    • RX-0201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-3117
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-5902
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-0047N
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-0201N
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-1792
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-21101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-8243
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Rexahn Pharmaceuticals, Inc. - Pipeline Analysis
    • Rexahn Pharmaceuticals, Inc. - Pipeline Products by Target
    • Rexahn Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Rexahn Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Rexahn Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Rexahn Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Rexahn Pharmaceuticals, Inc. - Dormant Projects
  • Rexahn Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Rexahn Pharmaceuticals, Inc., Key Information
  • Rexahn Pharmaceuticals, Inc., Key Facts
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Rexahn Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Rexahn Pharmaceuticals, Inc. - Phase II, 2015
  • Rexahn Pharmaceuticals, Inc. - Phase I, 2015
  • Rexahn Pharmaceuticals, Inc. - Preclinical, 2015
  • Rexahn Pharmaceuticals, Inc. - Discovery, 2015
  • Rexahn Pharmaceuticals, Inc. - Unknown, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Rexahn Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Rexahn Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Rexahn Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Rexahn Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Rexahn Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top